Financial Performance - The total operating revenue for 2024 was 51,089.06 million CNY, a decrease of 7.62% compared to the previous year[4] - The net profit attributable to the parent company was -17,923.07 million CNY, a decline of 728.52% year-on-year[4] - The basic earnings per share fell by 725.81% to -1.94 CNY[5] - The company experienced a 317.82% increase in net profit attributable to the parent company after excluding non-recurring gains and losses, totaling -24,315.82 million CNY[4] - The weighted average return on equity decreased by 6.55 percentage points to -5.70%[5] Assets and Equity - The total assets at the end of the reporting period were 330,909.69 million CNY, down 7.35% from the previous year[5] - The equity attributable to the parent company decreased by 8.49% to 308,144.19 million CNY[5] Research and Development - The R&D investment for 2024 reached 11,276.71 million CNY, accounting for 22.07% of the operating revenue[7] - The company reported an investment loss of 4,763.16 million CNY from joint ventures due to increased R&D expenditures[7] Impairment and Competition - A total of 8,478.31 million CNY was recognized as impairment losses on operating assets due to intensified industry competition[7]
热景生物(688068) - 2024 Q4 - 年度业绩